#4-93E. Navigating the Progressive Fibrotic Phenotype: Early Intervention in SSc-ILD (Arthritis Rheumatol, 2026)

Are we accurately predicting and effectively intervening early enough to halt the progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD)? This review synthesizes the evolving definitions of progressive pulmonary fibrosis (PPF), prognostic determinants, and the current therapeutic landscape for SSc-ILD, noting that up to 30% of patients transition to PPF. The paper highlights a critical paradigm shift: the growing emphasis on early combination therapies—utilizing immunosuppressants alongside antifibrotics—to prevent functional decline rather than waiting for advanced respiratory failure. While this proactive approach marks a significant clinical advancement, a critical appraisal of the current literature reveals a notable limitation: there is a distinct lack of high-quality, head-to-head comparative trials to confirm the optimal sequencing and specific combinations of these agents. Despite this knowledge gap, this review remains highly relevant for practicing physicians. It provides an essential, practical framework for identifying high-risk patients through multimodal screening and underscores the urgency of timely treatment escalation. By applying these insights, clinicians can refine their daily management of SSc-ILD and potentially alter the disease trajectory before irreversible lung damage occurs.

Citation: Benfaremo D, Allanore Y. Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis. Arthritis & Rheumatology. 2026. DOI: 10.1002/art.70237.

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.